LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical company engaged in the development and commercialization of human therapeutics, today announced that Shi Chung Ng, Ph.D., CytRx’s Senior Vice President of Research and Development, will present previously reported positive results of several animal stroke studies with the Company’s lead molecular chaperone amplification drug candidate arimoclomol at the Sixth International Workshop on The Molecular Biology of Stress Responses being held at the Chulabhorn Research Institute in Bangkok, Thailand.
